CFDA Reviews Spate Of J&J Product Recalls, Seeks Quality Commitments
This article was originally published in PharmAsia News
China FDA officials recently met with executives of Johnson & Johnson to review a spate of product recalls in China since 2009, with requesting the company to identify and rectify quality management system flaws by instituting risk control measures and adhering to Chinese laws and technical standards.
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.